leisure time -WSS

leisure time

author：comprehensive 2025-10-01 02:27:42 - browse：783

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What should King Charles tell the public about his cancer?

hotspot

WSS

PhRMA lawsuit over Medicare drug price negotiation tossed

Study suggests Covid rebound is far more common with Paxlovid than without

Medicare Advantage proposed rates disappoint insurers

What is STAT's opinion section for?

Readout LOUD podcast: How biotech is using artificial intelligence

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Drug repurposing or repositioning? The language matters

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

The cancer drug shortage isn’t new — and neither are the solutions

Key House Republican on health care plans exit from Congress

Bright Health sells Medicare Advantage business to Molina

What health policies could hitch a ride on a spending bill?

Moonlake's readout produced a cash windfall. Risks remain

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Supreme Court strikes down use of affirmative action

A letter from the executive editor: STAT UnitedHealth investigation

explore

Medical mystery: When a cough is not just a cough

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

For Medicare Advantage, Democrats want stronger protections around AI

PhRMA lawsuit over Medicare drug price negotiation tossed

Biden report: The neurospychology of memory and aging

Weight loss drugs should be covered by insurers, AMA says

leisure time

leisure time

hotspot

hotspot